Key Financial Figures - Half Year Ended September 30, 2026
Income Statement (₹ in Lakhs)
- Revenue from operations: ₹295.38 (compared to ₹407.48 in H1 FY26 and ₹956.50 in H2 FY26)
- Other income: ₹9.21 (compared to ₹7.23 in H1 FY26)
- Total income: ₹304.51 (compared to ₹414.71 in H1 FY26)
- Cost of material consumed: ₹209.67 (55% of revenue, improved from 61% in H1 FY26)
- Employee benefits expenses: ₹107.85 (increased from ₹84.26 in H1 FY26)
- Finance cost: ₹11.02 (decreased from ₹15.01 in H1 FY26)
- Depreciation and amortization: ₹3.58 (decreased from ₹4.63 in H1 FY26)
- Total expenses: ₹350.49
- Profit/(Loss) before tax: (₹45.98) loss (compared to ₹12.07 profit in H1 FY26)
- Tax expense: (₹2.58) [includes excess provision reversal of ₹2.48 and deferred tax of ₹0.10]
- Profit/(Loss) for the period: (₹43.40) net loss (compared to ₹9.04 profit in H1 FY26)
- Earnings per equity share (Basic & Diluted): (₹2.58) loss per share (compared to ₹0.54 profit in H1 FY26)
Balance Sheet Position as at September 30, 2026 (₹ in Lakhs)
- Total equity and liabilities: ₹1,736.28 (decreased from ₹1,873.14 as at March 31, 2026)
- Share capital: ₹168.15 (unchanged)
- Reserves and surplus: ₹993.75 (decreased from ₹1,037.15)
- Long term borrowing: ₹162.47 (decreased from ₹186.96)
- Short term borrowing: ₹103.61 (increased from ₹52.60)
- Trade payables: ₹235.85 (decreased from ₹268.63)
- Inventory: ₹186.25 (increased from ₹134.25)
- Trade receivables: ₹1,053.83 (decreased from ₹1,184.20)
- Cash and cash equivalents: ₹91.26 (decreased from ₹215.35)
Cash Flow Statement - Half Year Ended September 30, 2026 (₹ in Lakhs)
- Net cash flow from operating activities: (₹104.35) outflow
- Net cash flow from investing activities: (₹35.23) outflow
- Net cash flow from financing activities: ₹15.49 inflow
- Net decrease in cash and equivalents: ₹124.09
- Cash and equivalents at beginning: ₹215.35
- Cash and equivalents at end: ₹91.26
Management Commentary and Outlook
- This is the first loss reported since listing, with revenue decline attributed to seasonal patterns
- Company typically shows stronger performance in second half of financial year
- Current orders in hand: ₹5.74 crores
- Expected additional orders: ₹7 crores during the year
- Projected total revenue: approximately ₹16 crores (representing >15% growth over FY26)
- Trade receivables reduced by approximately ₹1.3 crores since March 2026
- Employee cost increase due to additional staff for geographical expansion
- Marketing expenses increased for future visibility and economic benefits
- Management expresses confidence in creating economic value for stakeholders
Regulatory and Procedural Details
- Board meeting held on November 13, 2026 (4:00 PM to 5:30 PM)
- Results reviewed by Audit Committee and approved by Board of Directors
- Statutory auditors S.P. Bhandare & Associates conducted limited review
- Financial statements prepared in accordance with Accounting Standards under Companies Act, 2013
- Company listed on SME Exchange, not required to comply with Indian Accounting Standards
- No subsidiaries, associates, or joint ventures
- Results disseminated on company website: www.epbiocomposites.com
IPO Proceeds Utilization
Company issued 5,04,000 equity shares of ₹10 each at ₹126 per share through IPO aggregating ₹635.00 lakhs. Net proceeds after expenses: ₹580.04 lakhs. Utilization as planned:
- Long term lease deposit for manufacturing facilities: ₹200.00 lakhs (fully utilized)
- Part repayment of loan: ₹80.00 lakhs (fully utilized)
- Funding working capital requirement: ₹151.18 lakhs (fully utilized)
- General corporate purpose: ₹148.86 lakhs (fully utilized)
Forward-Looking Statements Disclaimer
Management commentary contains forward-looking statements based on current perceptions and available information. Statements reflect current views of future events subject to risks and uncertainties including changes in general economic conditions. Company does not guarantee accuracy of assumptions underlying such statements.